Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 10/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.37 |
| ▸ | QPCT | Q16769 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918904 | 0.91 | POLB (0.37) | POLBPDE4APDE4DQPCTPDE4B | |
| SCHEMBL6747515 | 0.88 | POLB (0.39) | POLBPDE4APDE4DQPCTPDE4B | |
| SCHEMBL3921018 | 0.80 | PDE4B (0.44) | PDE4APDE4DPDE4BPDE4CRECQL | |
| SCHEMBL3998687 | 0.80 | PDE4B (0.45) | POLBPDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6747522 | 0.80 | POLB (0.38) | POLBPDE4APDE4DQPCTPDE4B | |
| SCHEMBL5094491 | 0.79 | ALDH1A1 (0.38) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL3920230 | 0.79 | HSP90AA1 (0.44) | — | |
| SCHEMBL3919259 | 0.76 | PDE4B (0.43) | PDE4APDE4DPDE4BPDE4CRECQL | |
| SCHEMBL3918229 | 0.75 | PDE4B (0.44) | POLBPDE4APDE4DPDE4BPDE4C | |
| SCHEMBL4001975 | 0.74 | CHRM4 (0.38) | PDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329736-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, CORP. (US) | 2012-12-11 | — | — | US | claimed |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-09 | — | — | US | claimed |
| US-8183384-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-22 | — | — | US | claimed |
| EP-2038262-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2009-03-25 | — | — | EP | claimed |
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | claimed |
| WO-2007139968-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | claimed |
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8329736-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8183384-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004277-A1 | Triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90B1, HSP90AA1 | POLB 1635/4885PDE4A 1902/4885PDE4D 2598/4885 |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | POLB 1635/4885PDE4A 1902/4885PDE4D 2598/4885 |
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | POLB 1635/4885PDE4A 1902/4885PDE4D 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.